Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-09-20FDA Approved: SARCLISA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for SARCLISA (isatuximab) submitted by Sanofi-Aventis U.S. LLC. The action represents an approva…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation [Phase 1, Phase 2]
Results from a Phase 1/2 study evaluating the WT1 peptide vaccine in patients with multiple myeloma after autologous stem cell transplantati…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 study to determine the dose and regimen of Durvalumab as monotherapy or in combination with Pomalidomide with or without Dexamethaso…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. [Phase 2]
Pfizer completed a Phase 2 study of elranatamab (PF-06863135) in Chinese participants with refractory/relapsed multiple myeloma, with result…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of carfilzomib with bendamustine and dexamethasone in multiple myeloma has been terminated; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma [NA]
This document describes a clinical trial evaluating ACT-001, an allogeneic anti-BCMA/GPRC5D bispecific CAR-NK cell therapy, for relapsed or …
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma [Phase 1, Phase 2]
This entry summarizes a Phase 1/2 clinical trial evaluating ixazomib in combination with pomalidomide, clarithromycin, and dexamethasone for…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
An ongoing clinical trial from Zhujiang Hospital is evaluating whether gut microbiota modulates immune responses in patients with monoclonal…
-
EMA approval · 2024-09-17EMA Authorised: Pomalidomide Accord (Pomalidomide) — Accord Healthcare S.L.U.
EMA authorised Pomalidomide Accord for the treatment of multiple myeloma. This authorisation adds a pomalidomide option to the market from A…
-
FDA approval · 2024-09-11FDA Approved: LENALIDOMIDE — Original Application (Novugen Pharma (USA) LLC)
FDA approved the original application for lenalidomide from Novugen Pharma (USA) LLC, enabling a generic version of the cancer drug lenalido…
-
FDA approval · 2024-09-10FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) submitted by U.S. Pharmaceuticals, resulting in updated labeling…
-
CLINICAL_TRIALS withdrawal · 2024-09-05Clinical Trial Update: 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy [Phase 2]
A Phase II randomized, open-label study evaluating an anti-SLAM monoclonal antibody as maintenance therapy in multiple myeloma has been with…
-
CLINICAL_TRIALS withdrawal · 2024-09-05Clinical Trial Update: A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma [Phase 1]
This clinical trial update indicates that Taiho Oncology’s Phase 1 dose-finding study followed by a safety and efficacy study in patients wi…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma [NA]
A multicenter Phase 2 trial evaluating subcutaneous isatuximab in combination with bortezomib, lenalidomide, and dexamethasone for newly dia…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating pembrolizumab in combination with radiation therapy for relapsed or refractory multiple myeloma; resu…
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma [Phase 1]
Pfizer's Phase 1 trial of Maplirpacept (PF-07901801) in advanced hematologic malignancies, including diffuse large B-cell lymphoma, acute my…
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 study of CC-99712, a BCMA-directed antibody-drug conjugate, in relapsed and refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS research · 2024-08-30Clinical Trial Update: Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating ixazomib for prophylaxis of chronic graft-versus-host disease after hematopoietic stem cell transplantat…
-
CLINICAL_TRIALS research · 2024-08-28Clinical Trial Update: Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma [EARLY_Phase 1]
This entry reports an early-phase study evaluating CD38-CS1 CAR-T cells for refractory or recurrent multiple myeloma, sponsored by The Secon…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy [Phase 2]
This Phase 2 trial assesses the safety and immunogenicity of the Moderna COVID-19 vaccine (mRNA-1273) in patients with solid tumors and hema…
-
FDA approval · 2024-08-26FDA Approved: BORUZU — Original Application (Amneal Pharmaceuticals LLC)
FDA approved BORUZU (bortezomib) from Amneal Pharmaceuticals as an original NDA. The approval covers indications including multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
This clinical trial update reports the incidence of hyperpigmentation in Black patients with multiple myeloma treated with immunomodulatory …
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
This Phase 1 study evaluated the safety and preliminary efficacy of combining metformin, nelfinavir, and bortezomib in patients with relapse…
-
CLINICAL_TRIALS other · 2024-08-21Clinical Trial Update: Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant [Phase 2]
Clinical Trial Update for a phase 2 study of lenalidomide and dexamethasone with donor lymphocyte infusion in relapsed multiple myeloma afte…
-
CLINICAL_TRIALS research · 2024-08-19Clinical Trial Update: FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) [Phase 3]
Phase 3 clinical trial (HOVON174MM) evaluating a treatment-free interval in newly diagnosed multiple myeloma patients treated with daratumum…